



HCSPharma

**World first:
HCS Pharma launches crypto fundraising,
before its IPO, to support its development**

**French biotech innovator announces the opening of a Security Token Offering (STO),
after raising a record €2M on Capital cell**

Paris, 8 April 2022 - [HCS Pharma](#), the French biotech company that develops in-vitro organs using its BIOMIMESYS® technology, is announcing the public opening of an STO (Security Token Offering) as of 8 April, 2022, on the [EDSX](#) platform. With the opening of its capital, HCS Pharma confirms its wish to strengthen its position as a developer of solutions in Regenerative Medicine & Cellular Therapy.

World first: opening the capital of a biotech to Crypto investors

HCS Pharma is innovating in this area by opening its capital to crypto investors, who are known to be more agile, extremely curious and constantly seeking to anchor their investment in the concrete innovations that will shape the future.

The Security Token Offering format will give them access to HCS Pharma's capital, as soon as it is listed on the stock exchange. The objective of the STO is to raise between 5 and 7 million euros. The opening of the sale to the public is 8 April, 2022.

HCS Pharma's STO is also supported by Hash Consulting and Markchain, the two leading communication agencies specialised in digital assets.

Record fundraising with Capital Cell

In less than 24 hours, HCS Pharma has raised €2M on Capital Cell, the 1st European platform for participative financing dedicated to healthcare.

By Capital Cell's own admission, the hype surrounding HCS Pharma is unprecedented.

"There has been real investor interest in HCS Pharma", Teodor de Mas - Investment Director at Capital Cell

"We are delighted with the success of the HCS Pharma fundraising, a pioneering transaction for Cell Capital that marks a fantastic start to our expansion plans in Europe", Daniel Oliver - Director at Capital Cell.



HCSPharma

Pre-IPO funding

This fundraising campaign is part of a global approach whose objective is to provide HCS Pharma with the means for its long-term development.

Following the STO, HCS Pharma will focus on its planned listing on the Frankfurt Stock Exchange in Q3 2022 and on the Nasdaq in New York within the next 12 months. The tokens acquired through the STO will be converted into shares of the company as soon as the listing is effective.

This listing will also free up the USD 20 million financing secured from an American family office.

To learn more, go to: <http://invest.hcs-pharma.com/>

About HCS Pharma

HCS Pharma is a biotechnology company that develops and distributes products for growing human or animal cells in an artificially created organ-like environment. Its technology is based on a 3D cell culture system that best replicates the biological environment and enables better results for research and biological testing. HCS Pharma's flagship product is BIOMIMESYS® Hydro scaffold™ which is offered to its customers from various industries such as pharmaceutical, dermo-cosmetic and food industries.

To learn more, go to: <https://invest.hcs-pharma.com/>

Press contact

Lindsey Williams - lindseywilliams@storiesout.com - +33 (0)6 31 46 46 18